Metabolic Health 

GLP-1 medications such as semaglutide (Wegovy®) and tirzepatide (Mounjaro®) have transformed obesity treatment, helping many people achieve significant and sustained weight loss for the first time. But one question comes up in almost every time I discuss this topic: “What happens when I stop taking it?” The short answer is that it depends—but for many people, weight regain is common. That doesn’t mean the medication has “failed”, nor does it mean you’ve done anything wrong. I

Carbohydrates (CHO) are a fundamental energy source, supporting cellular function, physical activity, and metabolic processes. However, a growing body of research suggests that chronically elevated carbohydrate metabolism—particularly in the context of sustained high glucose availability—can influence key biological pathways linked to aging. One central mechanism involves mitochondrial function and oxidative stress. During carbohydrate metabolism, glucose is processed through

The rise of drugs like GLP-1 receptor agonists —including semaglutide and tirzepatide—has transformed obesity treatment. But alongside their success, a persistent concern has emerged: Are we trading fat loss for muscle loss? A new study published in Cell Reports Medicine offers a more reassuring—and nuanced—answer. The Concern: “Skinny Fat” from GLP-1 Drugs Rapid weight loss, especially from pharmacological interventions, has historically been associated with: Loss of lean b